Adma Biologics Inc (NASDAQ:ADMA) does about 2.80M shares in volume on a normal day but saw 1909777 shares change hands in Monday trading. The company now has a market cap of 1.42B USD. Its current market price is $6.22, marking a decrease of -2.66% compared to the previous close of $6.39. The 52 week high reached by this stock is $6.76 whilst the lowest price level in 52 weeks is $3.06.
Adma Biologics Inc (ADMA) has a 20-day trading average at $6.30 and the current price is -7.99% off the 52-week high compared with 103.27% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.77 and its 200-day simple moving average is $4.37. If we look at the stock’s price movements over the week, volatility stands at 3.22%, which increases to 3.48% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 52.40 to suggest the stock is neutral.
The consensus objective for the share price is $8.38, suggesting that the stock has a potential upside of 25.78% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 19, 2023 when Raymond James resumed the stock to “Strong Buy” and issued a price target of $5. Raymond James upgraded its price target at $5.
Adma Biologics Inc (ADMA) stock is down -4.89% over the week and 0.97% over the past month. Its price is 37.61% year-to-date and 96.21% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of -$0.08 below consensus estimates by -$0.1. ADMA’s earnings per share are forecast to grow by 330.80% this year and 66.70% over next year. Expected sales for next quarter are $81.27 million, which analysts say will come at $333.87 million for the current fiscal year and next year at $389.87 million. In addition, estimates put the company’s current quarterly revenue at an average of $77.27 million.
To reach the target analysts have set, the stock logically needs to grow 25.78 percent from here.
Outstanding shares total 226.06M with insiders holding 2.50% of the shares and institutional holders owning 77.30% of the company’s common stock. The company has a return on investment of -10.25% and return on equity of -19.67%. The forward price to earnings ratio is 12.44. The beta has a value of 0.43. Price to book ratio is 10.40 and price to sales ratio is 5.50.
